Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
Cancer Letters
|
April 24, 2016
PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia
Nina Yoo, Ha-Reum Lee, Su-Hyun Shin, et al.
Plos One
|
March 25, 2016
PLAG (1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol) Modulates Eosinophil Chemotaxis by Regulating CCL26 Expression from Epithelial Cells
Jinseon Jeong, Young-Jun Kim, Sun Young Yoon, et al.
International Journal of Pharmaceutics
|
May 31, 2012
In vitro and in vivo evaluation of N,N,N-trimethylphytosphingosine-iodide (TMP) in liposomes for the treatment of angiogenesis and metastasis
Chung Kil Song, Ju-Hee Lee, Alexander Jahn, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 4, 2021
Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved <i>N</i>-Acetylgalactosamine-Conjugated RNA Interference Therapeutic
Jing Li, Ju Liu, Xuemei Zhang, et al.
Journal of Medicinal Chemistry
|
February 7, 2003
Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction
Guixue Yu, Helen Mason, Ximao Wu, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 12, 2001
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664
Jagabandhu Das, S David Kimball, Steven E Hall, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 23, 2009
Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors
Yan Shi, Jing Zhang, Mengxiao Shi, et al.
Journal of Medicinal Chemistry
|
December 28, 2002
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist
Natesan Murugesan, Zhengxiang Gu, Steven Spergel, et al.
Journal of Medicinal Chemistry
|
August 23, 2002
Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists
Natesan Murugesan, John E Tellew, Zhengxiang Gu, et al.
Nucleic Acids Research
|
May 14, 2024
Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates
Mikyung Yu, June Qin, Xiumin Liu, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
Cancer Letters
|
April 24, 2016
PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia
Nina Yoo, Ha-Reum Lee, Su-Hyun Shin, et al.
Plos One
|
March 25, 2016
PLAG (1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol) Modulates Eosinophil Chemotaxis by Regulating CCL26 Expression from Epithelial Cells
Jinseon Jeong, Young-Jun Kim, Sun Young Yoon, et al.
International Journal of Pharmaceutics
|
May 31, 2012
In vitro and in vivo evaluation of N,N,N-trimethylphytosphingosine-iodide (TMP) in liposomes for the treatment of angiogenesis and metastasis
Chung Kil Song, Ju-Hee Lee, Alexander Jahn, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 4, 2021
Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved <i>N</i>-Acetylgalactosamine-Conjugated RNA Interference Therapeutic
Jing Li, Ju Liu, Xuemei Zhang, et al.
Journal of Medicinal Chemistry
|
February 7, 2003
Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction
Guixue Yu, Helen Mason, Ximao Wu, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 12, 2001
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664
Jagabandhu Das, S David Kimball, Steven E Hall, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 23, 2009
Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors
Yan Shi, Jing Zhang, Mengxiao Shi, et al.
Journal of Medicinal Chemistry
|
December 28, 2002
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist
Natesan Murugesan, Zhengxiang Gu, Steven Spergel, et al.
Journal of Medicinal Chemistry
|
August 23, 2002
Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists
Natesan Murugesan, John E Tellew, Zhengxiang Gu, et al.
Nucleic Acids Research
|
May 14, 2024
Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates
Mikyung Yu, June Qin, Xiumin Liu, et al.
Page
of 6